14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Mar 22, 2018 $61.94 $64.26 $60.79 $61.01 842 330
Mar 21, 2018 $59.46 $62.62 $58.07 $62.16 715 514
Mar 20, 2018 $61.91 $62.41 $58.11 $59.75 913 951
Mar 19, 2018 $61.45 $63.04 $59.58 $61.39 824 384
Mar 16, 2018 $64.88 $64.88 $61.59 $61.81 930 084
Mar 15, 2018 $63.11 $64.94 $62.06 $64.38 1 172 767
Mar 14, 2018 $64.84 $65.40 $61.64 $62.69 817 371
Mar 13, 2018 $68.00 $68.53 $63.00 $64.60 1 434 902
Mar 12, 2018 $68.41 $69.57 $66.75 $67.72 801 777
Mar 09, 2018 $69.83 $69.88 $66.06 $68.12 832 770
Mar 08, 2018 $65.46 $70.70 $65.46 $69.44 1 632 337
Mar 07, 2018 $62.56 $66.95 $62.00 $65.76 1 713 097
Mar 06, 2018 $59.80 $62.94 $59.18 $62.18 1 145 381
Mar 05, 2018 $57.82 $60.45 $57.40 $59.57 1 190 580
Mar 02, 2018 $54.86 $57.85 $53.75 $57.68 1 137 524
Mar 01, 2018 $54.78 $58.33 $54.78 $55.84 1 557 953
Feb 28, 2018 $56.07 $56.90 $52.20 $55.23 4 723 889
Feb 27, 2018 $60.30 $64.44 $60.00 $61.55 959 226
Feb 26, 2018 $60.50 $61.00 $58.51 $59.77 1 007 421
Feb 23, 2018 $61.07 $61.99 $59.75 $60.74 621 143
Feb 22, 2018 $64.10 $64.94 $60.06 $60.89 715 917
Feb 21, 2018 $62.12 $65.82 $60.66 $62.01 808 032
Feb 20, 2018 $59.85 $62.59 $59.50 $62.30 1 062 256
Feb 16, 2018 $60.60 $62.75 $60.00 $60.00 664 042
Feb 15, 2018 $62.24 $62.60 $60.94 $61.03 506 850
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT